In an 80‑year‑old man with benign prostatic hyperplasia and no known prostate cancer, how often should prostate‑specific antigen (PSA) testing be performed?

PSA Screening Frequency in an 80-Year-Old Man with BPH

In an 80-year-old man with benign prostatic hyperplasia, routine PSA screening should be discontinued unless he is exceptionally healthy with minimal comorbidity, prior elevated PSA values, and documented life expectancy exceeding 10–15 years—in which case testing every 1–2 years may be considered. 1, 2

Evidence Against Routine Screening at Age 80

• Randomized trial evidence demonstrates no mortality benefit from PSA screening in men aged 70 years or older. The European Randomized Study of Screening for Prostate Cancer (ERSPC) showed no reduction in prostate cancer mortality among men ≥70 years. 1

• Men aged 75 years or older with PSA <3.0 ng/mL have only a 0.2% risk of dying from prostate cancer and may safely discontinue screening. 1, 2, 3 At age 80, competing mortality from other causes far exceeds any potential benefit from cancer detection. 1

• The harms of screening increase substantially with age. Among men over 80 years, three-fourths or more of screen-detected cancers with PSA <10 ng/mL and Gleason score ≤6 represent overdiagnosis. 1 These men will experience the harms of biopsy and potential overtreatment without meaningful survival benefit.

When Continued Screening May Be Justified

For the rare 80-year-old in exceptional health, screening intervals should be risk-stratified by PSA level:

• PSA <1.0 ng/mL: Repeat every 2–4 years 1, 2
• PSA 1.0–2.5 ng/mL: Repeat every 1–2 years 1, 2
• PSA ≥2.5 ng/mL: Annual testing with consideration for further evaluation 1, 2

However, this approach should be reserved only for men with:

• Minimal or no comorbidities 1
• Prior elevated PSA values suggesting higher baseline risk 1, 2
• Documented life expectancy >10–15 years based on health status and family longevity 1, 2

Rationale for Discontinuation

• The median age of death from prostate cancer is 80 years, and 75% of men with localized prostate cancer die of other causes rather than their cancer. 2 This patient has already reached the median age of prostate cancer death.

• Treatment harms outweigh benefits in older men. Even if cancer is detected, men with limited life expectancy (<10 years) experience no mortality benefit from treatment, only the morbidity of erectile dysfunction, urinary incontinence, and bowel dysfunction. 1, 4

• Benign prostatic hyperplasia itself elevates PSA, reducing the specificity of the test. 5, 6 In elderly men with BPH, PSA values between 4–10 ng/mL are commonly due to prostate volume rather than malignancy. 5

Practical Algorithm for This Patient

1. Assess life expectancy: If <10 years due to age, comorbidities, or functional status → Stop screening 1, 2

2. If life expectancy >10–15 years AND patient is in exceptional health:

   • Check current PSA level
   • If PSA <3.0 ng/mL → Stop screening 1, 2, 3
   • If PSA ≥3.0 ng/mL → Consider continued surveillance every 1–2 years 1, 2

3. Document shared decision-making discussing that at age 80, the absolute harms (false-positives, unnecessary biopsies, overtreatment) exceed any potential mortality benefit 1, 4

Common Pitfalls to Avoid

• Do not continue annual screening reflexively in elderly men simply because it was done previously. The benefit-to-harm ratio declines sharply after age 70. 1

• Do not screen men with significant comorbidities (heart failure, COPD, diabetes with complications) regardless of PSA history, as they will not live long enough to benefit. 1, 2

• Do not use a PSA threshold of 4.0 ng/mL in elderly men with BPH without considering prostate volume and PSA density, as BPH commonly elevates PSA independent of malignancy. 5, 6